Market Overview

JMP: Time To Buy Axovant Sciences, Probability For RVT-101 Success 'High'


In a report published Wednesday, JMP Securities analyst Jason N. Butler initiated coverage of Axovant Sciences Ltd (NYSE: AXON) with a Market Outperform rating and a price target of $36.

Axovant is a biopharmaceutical company focused on the development and commercialization of novel treatments for dementia, including Alzheimer's disease (AD). The company is conducting a confirmatory Phase 3 trial for RVT-101, its lead candidate, as an adjunct therapy to donepezil in patients with mild-to moderate AD.

"We believe the probability of success for this Phase 3 trial is high, based on a clear mechanistic rationale for synergistic benefits with donepezil, and positive results from a large randomized, controlled, Phase 2b trial in the same patient population," analyst Jason N. Butler wrote.

In the report JMP Securities noted, "RVT-101 is being developed as an add-on therapy to donepezil and there is both mechanistic and clinical evidence to support clinically important benefits of combining these drug modalities. We also see commercial advantages to an add-on therapy, with targeted patients already receiving treatment for their disease, which we believe will speed RVT-101's adoption."

Positive trial results could lead to a possible FDA approval and launch by 2019.

Axovant's shares are up nearly 15 percent since the company's IPO in June 2015. "We anticipate that the stock can continue to appreciate in coming months as the company executes on its Phase 3 trial for RVT-101 in AD and advances clinical development of the candidate in additional dementia indications," the report added.

Latest Ratings for AXON

Dec 2018UpgradesHoldBuy
Jan 2018DowngradesOutperformMarket Perform
Jan 2018UpgradesSellNeutral

View More Analyst Ratings for AXON
View the Latest Analyst Ratings

Posted-In: JMP SecuritiesAnalyst Color Initiation Analyst Ratings


Related Articles (AXON)

View Comments and Join the Discussion!

Latest Ratings

HTHTDaiwa CapitalDowngrades
GSKNew StreetUpgrades
JNJCredit SuisseMaintains158.0
TDGCredit SuisseMaintains584.0
SCHWDeutsche BankReiterates35.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

USD/CAD Mostly Higher

Delta Air Q2 Profit Tops Views